A Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin With Radiation Therapy Followed by Pemetrexed in Patients With Inoperable Non-Small-Cell Lung Cancer
NCT00482014
Completed
The primary purpose of this study is to determine the 2-year survival rate of both of the chemotherapy regimens in patients with inoperable non-small-cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/26/2012
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Memphis, Tennessee
Conditions: Non-Small-Cell Lung Cancer
Register for Updates
SWOG-9416: Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Stage III Non-small Cell Lung Cancer
NCT00002642
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to kill tumor cells. Combining radiation therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of chemotherapy using cisplatin and etoposide, radiation therapy, and surgery, with adjuvant therapy using cisplatin and etoposide, in treating patients who have stage III non-small cell lung... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/05/2012
Locations: Vanderbilt Cancer Center, Nashville, Tennessee
Conditions: Lung Cancer
Register for Updates
Irinotecan and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
NCT00639769
Completed
RATIONALE: Drugs used in chemotherapy, such as irinotecan and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: To determine if CPT-11 given together with cisplatin is effective in treating recurrent or metastatic head and neck cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/07/2012
Locations: Erlanger Health System, Chattanooga, Tennessee +6 locations
Conditions: Head and Neck Cancer
Register for Updates
S0227 Cisplatin With Either Paclitaxel or Gemcitabine in Recurrent, Persistent, or Metastatic Cervical Cancer
NCT00057928
Withdrawn
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether cisplatin is more effective when combined with paclitaxel or gemcitabine in treating cervical cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of cisplatin combined with paclitaxel to that of cisplatin combined with gemcitabine in treating women who have recurrent, persi... Read More
Gender:
FEMALE
Ages:
All
Trial Updated:
06/11/2012
Locations: University of Tennessee Cancer Institute, Memphis, Tennessee
Conditions: Cervical Cancer
Register for Updates
A Study of Telatinib in Combination With Chemotherapy in Subjects With Advanced Gastric Cancer
NCT00952497
Completed
The objectives of this study are to evaluate the anti-tumor activity, safety, and tolerability of telatinib when used in combination with chemotherapy (capecitabine and cisplatin) as first-line therapy in subjects with advanced gastric cancer. The primary objective is to assess progression free survival (PFS) in subjects receiving telatinib in combination with chemotherapy (capecitabine and cisplatin). The secondary objectives are to assess overall survival, overall response rate, safety and tol... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/07/2012
Locations: The West Clinic, Memphis, Tennessee
Conditions: Gastric Cancer
Register for Updates
Tirapazamine Plus Cisplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
NCT00020696
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining tirapazamine with cisplatin in treating patients who have recurrent ovarian epithelial or primary peritoneal cancer.
Gender:
FEMALE
Ages:
All
Trial Updated:
01/07/2012
Locations: Brookview Research, Inc., Nashville, Tennessee
Conditions: Ovarian Cancer, Primary Peritoneal Cavity Cancer
Register for Updates
S0216, Combination Chemotherapy and RT in Treating Patients With Stage III or Stage IV Head and Neck Cancer
NCT00054054
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one chemotherapy drug with radiation therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy and radiation therapy in treating patients with stage III or stage IV head and neck cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2011
Locations: University of Tennessee Cancer Institute, Memphis, Tennessee
Conditions: Head and Neck Cancer
Register for Updates
TLK286 (Telcyta) in Combination With Cisplatin for Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
NCT00077883
Completed
The purpose of this trial is to study the efficacy and safety of the combination of TLK286 with cisplatin as first-line therapy for patients with locally advanced or metastatic non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2011
Locations: The Sarah Cannon Cancer Center, Nashville, Tennessee
Conditions: Non-small Cell Lung Cancer
Register for Updates
Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer
NCT00083083
Unknown
RATIONALE: Imaging procedures, such as fludeoxyglucose F18 positron emission tomography (\^18FDG-PET), may improve the ability to detect disease progression and help doctors predict a patient's response to treatment and plan more effective treatment. PURPOSE: This phase II trial is studying how well \^18FDG-PET imaging works in detecting disease progression and determining response to treatment in patients who are undergoing chemoradiotherapy for locally advanced non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/26/2011
Locations: Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
Conditions: Lung Cancer
Register for Updates
Gemcitabine or Gemcitabine Plus Docetaxel After Cisplatin, Etoposide and Radiation in Non Small Cell Lung Cancer (NSCLC)
NCT00191139
Completed
To assess the 2 year survival of patients with Stage III unresectable non-small cell lung cancer receiving consolidation gemcitabine or gemcitabine plus docetaxel following concurrent chemotherapy and radiation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/04/2010
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal ph, Memphis, Tennessee
Conditions: Non-small Cell Lung Cancer
Register for Updates
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
NCT00053105
Unknown
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase I trial to study the effect of combination chemotherapy on the body when treating patients who have relapsed or refractory aggressive non-Hodgkin's lymphoma.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
07/04/2009
Locations: Boston Baskin Cancer Group, University Tennessee, Memphis, Tennessee
Conditions: Lymphoma
Register for Updates
Therapy for Children With Advanced Stage High Risk Neuroblastoma
NCT00186849
Completed
This is a Phase II pilot study of chemotherapy and surgery for children with advanced stage high-risk neuroblastoma utilizing topotecan during an upfront window and other active agents during induction and intensification phases. The primary purpose is to estimate the response rate to an upfront window of two cycles of intravenous topotecan. We hypothesize that the topotecan window will be an effective therapy in terms of the response rate.
Gender:
ALL
Ages:
18 years and below
Trial Updated:
05/19/2009
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Neuroblastoma
Register for Updates